U.S. ARKRAY Inc (ARKRAY) reported on Monday the availability of the ADAMS A1c HA-8180V system for haemoglobin A1c testing for the diagnosis of diabetes.

The company said the ADAMS A1c HA-8180V system passed US FDA 510(k) clearance as an aid in the diagnosis and monitoring of individuals with diabetes.

According to the company, the ADAMS A1c HA-8180V system is simple to operate and generates results in ninety seconds. Calibration and maintenance are minimized with the integrated column and pre-filter. Hands-on time is reduced with primary tube cap-piercing sampling and no sample pre-treatment.

In conjunction, the company said its ADAMS A1c HA-8180V improves outcomes generating the quality results required to assess patient care. The fully automated analyzer utilizes gold standard HPLC technology. Providing superior precision with CV's of 1% or lower offers clinicians confidence diagnosing and treating diabetes. The early detection and treatment of diabetes can decrease the risk of developing long-term complications.

US ARKRAY Inc is a urinalysis company and is a wholly owned subsidiary of ARKRAY Inc of Kyoto, Japan.